Minerva Neurosciences (NERV) Operating Expenses (2013 - 2026)

Minerva Neurosciences has reported Operating Expenses for 14 years, with the latest figure at $16.7 million in Q1 2026.

• For the quarter ending Q1 2026, Operating Expenses rose 327.16% year-over-year to $16.7 million; the trailing twelve-month figure through Mar 2026 stood at $27.9 million (up 46.16% YoY), and the FY2025 full-year result was $15.1 million, down 30.87% from the prior year.
• Operating Expenses for Q1 2026 stood at $16.7 million, up from $5.0 million in the prior quarter.
• The five-year high for Operating Expenses was $16.7 million in Q1 2026, with the low at $2.8 million in Q3 2025.
• Historically, Operating Expenses has averaged $6.0 million across 5 years, with a median of $5.2 million in 2022.
• Annual changes were most pronounced in 2022 — Operating Expenses sank 76.28% — and 2026, when it surged 327.16%.
• Minerva Neurosciences' Operating Expenses stood at $5.1 million in 2022, then jumped by 41.47% to $7.2 million in 2023, then tumbled by 36.95% to $4.5 million in 2024, then advanced by 10.16% to $5.0 million in 2025, then soared by 234.66% to $16.7 million in 2026.
• The last three Operating Expenses figures came in at $16.7 million (Q1 2026), $5.0 million (Q4 2025), and $2.8 million (Q3 2025), per Business Quant data.